Benzinga
10 Nov 2025, 17:30 UTC · 48w ago
Verdict
Headline takes no side. We score ANAB +0.70 — strongly bullish.
+0.70strongly bullish
More positive than 85% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
Which stocks this story touches
More positive than 85% of ticker scores this week
AnaptysBio released positive Phase 2 trial data for rosnilimab in ulcerative colitis, a significant clinical milestone.
Continue reading
5 related stories
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
22h ago
+76.6%
Price agrees with the score
$46.67 vs $26.43 close before publication (Nov 7) · not market-adjusted
ANAB chart →
